Drugs Made In America Acquisition II Corp. Fundamental Analysis
Drugs Made In America Acquisition II Corp. Fundamental Analysis
Drugs Made In America Acquisition II Corp. (DMIIR) shows weak financial fundamentals with a PE ratio of 0.60, profit margin of 0.00%, and ROE of 2.35%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 31.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze DMIIR's fundamental strength across five key dimensions:
Efficiency Score
WeakDMIIR struggles to generate sufficient returns from assets.
Valuation Score
ExcellentDMIIR trades at attractive valuation levels.
Growth Score
WeakDMIIR faces weak or negative growth trends.
Financial Health Score
ModerateDMIIR shows balanced financial health with some risks.
Profitability Score
WeakDMIIR struggles to sustain strong margins.
Key Financial Metrics
Is DMIIR Expensive or Cheap?
P/E Ratio
DMIIR trades at 0.60 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, DMIIR's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Drugs Made In America Acquisition II Corp. at 0.01 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -4.38 times EBITDA. This is generally considered low.
How Well Does DMIIR Make Money?
Net Profit Margin
For every $100 in sales, Drugs Made In America Acquisition II Corp. keeps $0.00 as profit after all expenses.
Operating Margin
Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $2.35 in profit for every $100 of shareholder equity.
ROA
Drugs Made In America Acquisition II Corp. generates $1.68 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $-0.01 in free cash annually.
FCF Yield
DMIIR converts -14.08% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
0.60
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.00
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.01
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.001
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.53
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.02
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
-0.00
vs 25 benchmark
How DMIIR Stacks Against Its Sector Peers
| Metric | DMIIR Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 0.60 | 21.32 | Better (Cheaper) |
| ROE | 2.35% | 644.00% | Weak |
| Net Margin | 0.00% | -827.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 1.49 | Strong (Low Leverage) |
| Current Ratio | 0.53 | 922.87 | Weak Liquidity |
| ROA | 1.68% | 13795.00% | Weak |
DMIIR outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Drugs Made In America Acquisition II Corp.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Value, Dividend, Cyclical
EPS CAGR
N/A
Industry Style: Value, Dividend, Cyclical
FCF CAGR
N/A
Industry Style: Value, Dividend, Cyclical